Targeting the Epithelium-Derived Innate Cytokines: From Bench to Bedside

키워드

참고문헌 (204)

1. Larsen SB, "Epithelial cells : liaisons of immunity", Curr Opin Immunol, 62, pp.45~53 (2020)
2. Hammad H, "Barrier epithelial cells and the control of type 2 immunity", Immunity, 43, pp.29~40 (2015)
3. Oppenheim JJ, "Alarmins : chemotactic activators of immune responses", Curr Opin Immunol, 17, pp.359~365 (2005)
4. Fang M, "IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment", Cancer Res, 77, pp.2735~2745 (2017)
5. Gamez C, "Lower cord blood IL-17 and IL-25, but not other epithelial cell-derived cytokines are associated with atopic dermatitis in infancy", Int Arch Allergy Immunol, 182, pp.474~478 (2021)
6. Kleinschek MA, "IL-25 regulates Th17 function in autoimmune inflammation", J Exp Med, 204, pp.161~170 (2007)
7. Li M, "IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL", 6 mice, 2012, pp.247, 25~31
8. Liu B, "IL-33", ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy, 2016, pp.113, E7572~E7579
9. Papp KA, "Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis", N Engl J Med, 366, pp.1181~1189 (2012)
10. Zeng F, "An autocrine circuit of IL-33 in keratinocytes is involved in the progression of psoriasis", J Invest Dermatol, 141, pp.596~606 (2021)
11. Kakkar R, "The IL-33", ST2 pathway : therapeutic target and novel biomarker, 2008, pp.7, 827~840
12. Moussion C, "The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?", PLoS One, 3, pp.e3331~ (2008)
13. Cayrol C, "Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33", Nat Immunol, 19, pp.375~385 (2018)
14. Lefrançais E, "IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G", Proc Natl Acad Sci U S A, 109, pp.1673~1678 (2012)
15. Roy A, "Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33(IL-33)and limits danger-induced inflammation", J Biol Chem, 289, pp.237~250 (2014)
16. Brusilovsky M, "Environmental allergens trigger type 2 inflammation through ripoptosome activation", Nat Immunol, 22, pp.1316~1326 (2021)
17. Cayrol C, "Interleukin-33(IL-33) : a nuclear cytokine from the IL-1 family", Immunol Rev, 281, pp.154~168 (2018)
18. Cherry WB, "A novel IL-1 family cytokine, IL-33, potently activates human eosinophils", J Allergy Clin Immunol, 121, pp.1484~1490 (2008)
19. Martin NT, "Interleukin 33 is a guardian of barriers and a local alarmin", Nat Immunol, 17, pp.122~131 (2016)
20. Vuvi G. Tran, "IL-33 Priming Enhances Peritoneal Macrophage Activity in Response to Candida albicans", Immune Network, 14(4), pp.201~206 (2014), 대한면역학회
21. Lefrançais E, "Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells", Proc Natl Acad Sci U S A, 111, pp.15502~15507 (2014)
22. Travers J, "Chromatin regulates IL-33 release and extracellular cytokine activity", Nat Commun, 9, pp.3244~ (2018)
23. McGeachy MJ, "The IL-17 family of cytokines in health and disease", Immunity, 50, pp.892~906 (2019)
24. Borowczyk J, "IL-25(IL-17E)in epithelial immunology and pathophysiology", J Allergy Clin Immunol, 148, pp.40~52 (2021)
25. Fort MM, "IL-25induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo", Immunity, 15, pp.985~995 (2001)
26. Kouzaki H, "Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells", Am J Respir Cell Mol Biol, 49, pp.741~750 (2013)
27. Min HK, "Interleukin(IL)-25 suppresses IL-22-induced osteoclastogenesis in rheumatoid arthritis via STAT3 and p38 MAPK", IκBα pathway, 2020, pp.22, 222~
28. Sonobe Y, "Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cepsilon-dependent manner", J Biol Chem, 284, pp.31834~31842 (2009)
29. Owyang AM, "Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract", J Exp Med, 203, pp.843~849 (2006)
30. Tamachi T, "IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice", J Allergy Clin Immunol, 118, pp.606~614 (2006)
31. Goswami S, "Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma", Nat Immunol, 10, pp.496~503 (2009)
32. Park LS, "Cloning of the murine thymic stromal lymphopoietin(TSLP)receptor : formation of a functional heteromeric complex requires interleukin 7 receptor", J Exp Med, 192, pp.659~670 (2000)
33. Quentmeier H, "Cloning of human thymic stromal lymphopoietin(TSLP)and signaling mechanisms leading to proliferation", Leukemia, 15, pp.1286~1292 (2001)
34. Rochman Y, "Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling", Proc Natl Acad Sci U S A, 107, pp.19455~19460 (2010)
35. Dong H, "Distinct roles of short and long thymic stromal lymphopoietin isoforms in house dust mite-induced asthmatic airway epithelial barrier disruption", Sci Rep, 6, pp.39559~ (2016)
36. Fornasa G, "Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin", J Allergy Clin Immunol, 136, pp.413~422 (2015)
37. Varricchi G, "Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer", Front Immunol, 9, pp.1595~ (2018)
38. Soumelis V, "Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP", Nat Immunol, 3, pp.673~680 (2002)
39. Ying S, "Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease", J Immunol, 181, pp.2790~2798 (2008)
40. Nagarkar DR, "Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis", J Allergy Clin Immunol, 132, pp.593~600 (2013)
41. Poposki JA, "Proprotein convertases generate a highly functional heterodimeric form of thymic stromal lymphopoietin in humans", J Allergy Clin Immunol, 139, pp.1559~1567 (2017)
42. Busse WW, "Asthma", N Engl J Med, 344, pp.350~362 (2001)
43. Allakhverdi Z, "Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells", J Exp Med, 204, pp.253~258 (2007)
44. Kato A, "TLR3-and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells", J Immunol, 179, pp.1080~1087 (2007)
45. Gudbjartsson DF, "Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction", Nat Genet, 41, pp.342~347 (2009)
46. He JQ, "A thymic stromal lymphopoietin gene variant is associated with asthma and airway hyperresponsiveness", J Allergy Clin Immunol, 124, pp.222~229 (2009)
47. Moffatt MF, "A large-scale, consortium-based genomewide association study of asthma", N Engl J Med, 363, pp.1211~1221 (2010)
48. Corrigan CJ, "Allergeninduced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses", J Allergy Clin Immunol, 128, pp.116~124 (2011)
49. Cheng D, "Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma", Am J Respir Crit Care Med, 190, pp.639~648 (2014)
50. Li Y, "Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo : a potential biomarker of severe refractory disease", J Immunol, 200, pp.2253~2262 (2018)
51. Préfontaine D, "Increased IL-33 expression by epithelial cells in bronchial asthma", J Allergy Clin Immunol, 125, pp.752~754 (2010)
52. Ballantyne SJ, "Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma", J Allergy Clin Immunol, 120, pp.1324~1331 (2007)
53. Kabata H, "Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation", Mucosal Immunol, 13, pp.626~636 (2020)
54. Liu X, "Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma", Biochem Biophys Res Commun, 386, pp.181~185 (2009)
55. Willebrand R, "IL-33-induced cytokine secretion and survival of mouse eosinophils is promoted by autocrine GM-CSF", PLoS One, 11, pp.e0163751~ (2016)
56. Salter BMA, "Human bronchial epithelial cell-derived factors from severe asthmatic subjects stimulate eosinophil differentiation", Am J Respir Cell Mol Biol, 58, pp.99~106 (2018)
57. Iikura M, "IL-33 can promote survival, adhesion and cytokine production in human mast cells", Lab Invest, 87, pp.971~978 (2007)
58. Saluja R, "The role of the IL-33", IL-1RL1 axis in mast cell and basophil activation in allergic disorders, 2015, pp.63, 80~85
59. Chang YJ, "Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity", Nat Immunol, 12, pp.631~638 (2011)
60. Bartemes KR, "IL-33-responsive lineage-CD25+ CD44(hi)lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs", J Immunol, 188, pp.1503~1513 (2012)
61. 우연덕, "The Roles of Innate Lymphoid Cells in the Development of Asthma", Immune Network, 14(4), pp.171~181 (2014), 대한면역학회
62. Kim HY, "Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity", J Allergy Clin Immunol, 129, pp.216~227 (2012)
63. Wang C, "IL-25 promotes Th2 immunity responses in asthmatic mice via nuocytes activation", PLoS One, 11, pp.e0162393~ (2016)
64. Toki S, "TSLP and IL-33 reciprocally promote each other’s lung protein expression and ILC2 receptor expression to enhance innate type-2 airway inflammation", Allergy, 75, pp.1606~1617 (2020)
65. Liu S, "Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma : the role of thymic stromal lymphopoietin", J Allergy Clin Immunol, 141, pp.257~268 (2018)
66. Kabata H, "Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation", Nat Commun, 4, pp.2675~ (2013)
67. Van Dyken SJ, "A tissue checkpoint regulates type 2 immunity", Nat Immunol, 17, pp.1381~1387 (2016)
68. Bredo G, "Interleukin-25initiates Th2 differentiation of human CD4(+)T cells and influences expression of its own receptor", Immun Inflamm Dis, 3, pp.455~468 (2015)
69. Jang S, "TSLP promotes induction of Th2 differentiation but is not necessary during established allergen-induced pulmonary disease", PLoS One, 8, pp.e56433~ (2013)
70. Smithgall MD, "IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells", Int Immunol, 20, pp.1019~1030 (2008)
71. Burzyn D, "Regulatory T cells in nonlymphoid tissues", Nat Immunol, 14, pp.1007~1013 (2013)
72. Sakaguchi S, "The plasticity and stability of regulatory T cells", Nat Rev Immunol, 13, pp.461~467 (2013)
73. Chen CC, "IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs", J Allergy Clin Immunol, 140, pp.1351~1363 (2017)
74. Ständer S, "Atopic dermatitis", N Engl J Med, 384, pp.1136~1143 (2021)
75. Eichenfield LF, "Atopic dermatitis and asthma : parallels in the evolution of treatment", Pediatrics, 111, pp.608~616 (2003)
76. Jariwala SP, "The role of thymic stromal lymphopoietin in the immunopathogenesis of atopic dermatitis", Clin Exp Allergy, 41, pp.1515~1520 (2011)
77. Nakamura N, "Stratum corneum interleukin-33 expressions correlate with the degree of lichenification and pruritus in atopic dermatitis lesions", Clin Immunol, 201, pp.1~3 (2019)
78. Savinko T, "IL-33 and ST2 in atopic dermatitis : expression profiles and modulation by triggering factors", J Invest Dermatol, 132, pp.1392~1400 (2012)
79. Wang YH, "IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLPDC-activated Th2 memory cells", J Exp Med, 204, pp.1837~1847 (2007)
80. Kim BS, "TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation", Sci Transl Med, 5, pp.170~ (2013)
81. Salimi M, "A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis", J Exp Med, 210, pp.2939~2950 (2013)
82. Ryu WI, "IL-33 down-regulates CLDN1 expression through the ERK", STAT3 pathway in keratinocytes, 2018, pp.90, 313~322
83. Seltmann J, "IL-33 impacts on the skin barrier by downregulating the expression of filaggrin", J Allergy Clin Immunol, 135, pp.1659~1661 (2015)
84. Hvid M, "IL-25 in atopic dermatitis : a possible link between inflammation and skin barrier dysfunction?", J Invest Dermatol, 131, pp.150~157 (2011)
85. Kim JH, "Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3(STAT3)and extracellular signal-regulated kinase(ERK)phosphorylation in keratinocytes", J Allergy Clin Immunol, 136, pp.205~208 (2015)
86. Leyva-Castillo JM, "ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation", J Allergy Clin Immunol, 145, pp.1606~1614 (2020)
87. Imai Y, "Skinspecific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice", Proc Natl Acad Sci U S A, 110, pp.13921~13926 (2013)
88. Yoo J, "Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin", J Exp Med, 202, pp.541~549 (2005)
89. Cork MJ, "Epidermal barrier dysfunction in atopic dermatitis", J Invest Dermatol, 129, pp.1892~1908 (2009)
90. Hirota T, "Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population", Nat Genet, 44, pp.1222~1226 (2012)
91. Paternoster L, "Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis", Nat Genet, 44, pp.187~192 (2011)
92. Paternoster L, "Multi-ancestry genome-wide association study of 21, 000 cases and 95, 000 controls identifies new risk loci for atopic dermatitis", Nat Genet, 47, pp.1449~1456 (2015)
93. Schleimer RP, "Etiology of epithelial barrier dysfunction in patients with type 2inflammatory diseases", J Allergy Clin Immunol, 139, pp.1752~1761 (2017)
94. Mashiko S, "Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis", J Dermatol Sci, 88, pp.167~174 (2017)
95. Wilson SR, "The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch", Cell, 155, pp.285~295 (2013)
96. Hashimoto Y, "Scratching of their skin by NC", Nga mice leads to development of dermatitis, 2004, pp.76, 783~794
97. Krueger JG, "Psoriasis pathophysiology : current concepts of pathogenesis", Ann Rheum Dis, 64(Suppl 2), pp.ii3030~ii36 (2005)
98. Chiang CC, "Neutrophils in Psoriasis", Front Immunol, 10, pp.2376~ (2019)
99. Li B, "The role of Th17 cells in psoriasis", Immunol Res, 68, pp.296~309 (2020)
100. Elloso MM, "Targeting the Th17 pathway in psoriasis", J Leukoc Biol, 92, pp.1187~1197 (2012)
101. Lowes MA, "Immunology of psoriasis", Annu Rev Immunol, 32, pp.227~255 (2014)
102. Mitsui A, "Serum IL-33 levels are increased in patients with psoriasis", Clin Exp Dermatol, 41, pp.183~189 (2016)
103. Suwarsa O, "Skin tissue expression and serum level of thymic stromal lymphopoietin in patients with psoriasis vulgaris", Dermatol Rep, 11, pp.8006~ (2019)
104. Duan Y, "IL-33 contributes to disease severity in Psoriasis-like models of mouse", Cytokine, 119, pp.159~167 (2019)
105. Hueber AJ, "IL-33 induces skin inflammation with mast cell and neutrophil activation", Eur J Immunol, 41, pp.2229~2237 (2011)
106. Suto H, "IL-25 enhances TH17 cell-mediated contact dermatitis by promoting IL-1β production by dermal dendritic cells", J Allergy Clin Immunol, 142, pp.1500~1509 (2018)
107. Volpe E, "Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis", J Allergy Clin Immunol, 134, pp.373~381 (2014)
108. Kubo T, "ΔNp63 controls a TLR3-mediated mechanism that abundantly provides thymic stromal lymphopoietin in atopic dermatitis", PLoS One, 9, pp.e105498~ (2014)
109. Gago-Lopez N, "Role of bulge epidermal stem cells and TSLP signaling in psoriasis", EMBO Mol Med, 11, pp.e10697~ (2019)
110. Trapp BD, "Multiple sclerosis : an immune or neurodegenerative disorder?", Annu Rev Neurosci, 31, pp.247~269 (2008)
111. Pichery M, "Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues : in situ analysis using a novel Il-33-LacZ gene trap reporter strain", J Immunol, 188, pp.3488~3495 (2012)
112. Fairlie-Clarke K, "Expression and function of IL-33", ST2axis in the central nervous system under normal and diseased conditions, 2018, pp.9, 2596~
113. Allan D, "Role of IL-33 and ST2 signalling pathway in multiple sclerosis : expression by oligodendrocytes and inhibition of myelination in central nervous system", Acta Neuropathol Commun, 4, pp.75~ (2016)
114. Christophi GP, "Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients", Clin Immunol, 142, pp.308~319 (2012)
115. Jiang HR, "IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages", Eur J Immunol, 42, pp.1804~1814 (2012)
116. Mado H, "Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability", Clin Neurol Neurosurg, 206, pp.106700~ (2021)
117. Jafarzadeh A, "Increased concentrations of interleukin-33 in the serum and cerebrospinal fluid of patients with multiple sclerosis", Oman Med J, 31, pp.40~45 (2016)
118. Sung HY, "Down-regulation of interleukin-33expression in oligodendrocyte precursor cells impairs oligodendrocyte lineage progression", J Neurochem, 150, pp.691~708 (2019)
119. Milovanovic M, "Deletion of IL-33R(ST2)abrogates resistance to EAE in BALB", C mice by enhancing polarization of APC to inflammatory phenotype, 2012, pp.7, e45225~
120. Javan MR, "Molecular analysis of interleukin-25 exons 1and 2 and its serum levels in Iranian patients with multiple sclerosis", Am J Clin Exp Immunol, 3, pp.91~96 (2014)
121. Turner DA, "IL-25 prevents T cell-mediated neurotoxicity by decreasing LFA-1expression", J Neuroimmunol, 265, pp.11~19 (2013)
122. Maiorino C, "Lentiviral-mediated administration of IL-25 in the CNS induces alternative activation of microglia", Gene Ther, 20, pp.487~496 (2013)
123. Eckhardt J, "Thymic stromal lymphopoietin deficiency attenuates experimental autoimmune encephalomyelitis", Clin Exp Immunol, 181, pp.51~64 (2015)
124. Yu X, "The autoimmune encephalitis-related cytokine TSLP in the brain primes neuroinflammation by activating the JAK2-NLRP3 axis", Clin Exp Immunol, 207, pp.113~122 (2021)
125. Hanahan D, "Hallmarks of cancer : the next generation", Cell, 144, pp.646~674 (2011)
126. Zhang J, "Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma", Int J Neurosci, 127, pp.210~217 (2017)
127. Chen SF, "The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma", J Pathol, 231, pp.180~189 (2013)
128. Sun P, "Serum interleukin-33 levels in patients with gastric cancer", Dig Dis Sci, 56, pp.3596~3601 (2011)
129. Liu X, "IL-33", ST2 pathway contributes to metastasis of human colorectal cancer, 2014, pp.453, 486~492
130. Zhang P, "Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications", J Int Med Res, 40, pp.1654~1661 (2012)
131. Santulli P, "Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden", Hum Reprod, 28, pp.2126~2133 (2013)
132. Hu LA, "Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer", Asian Pac J Cancer Prev, 14, pp.2563~2566 (2013)
133. Yang ZP, "The association of serum IL-33 and sST2 with breast cancer", Dis Markers, 2015, pp.516895~ (2015)
134. Jovanovic IP, "Interleukin-33", ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells, 2014, pp.134, 1669~1682
135. Gao X, "Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells", J Immunol, 194, pp.438~445 (2015)
136. Gao K, "Transgenic expression of IL-33 activates CD8(+)T cells and NK cells and inhibits tumor growth and metastasis in mice", Cancer Lett, 335, pp.463~471 (2013)
137. Qin L, "Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia", Oncotarget, 7, pp.61069~61080 (2016)
138. Dominguez D, "Exogenous IL-33 restores dendritic cell activation and maturation in established cancer", J Immunol, 198, pp.1365~1375 (2017)
139. Chen J, "Interleukin-33contributes to the induction of Th9 cells and antitumor efficacy by dectin-1-activated dendritic cells", Front Immunol, 9, pp.1787~ (2018)
140. Moral JA, "ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity", Nature, 579, pp.130~135 (2020)
141. Ikutani M, "Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity", J Immunol, 188, pp.703~713 (2012)
142. Wagner M, "Tumor-derived lactic acid contributes to the paucity of intratumoral ILC2s", Cell Rep, 30, pp.2743~2757 (2020)
143. Jiang Z, "IL-25 blockade inhibits metastasis in breast cancer", Protein Cell, 8, pp.191~201 (2017)
144. Nakajima R, "Interleukin-25 is involved in cutaneous T-cell lymphoma progression by establishing a T helper 2-dominant microenvironment", Br J Dermatol, 178, pp.1373~1382 (2018)
145. Ferretti E, "IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis", OncoImmunology, 7, pp.e1397249~ (2017)
146. Furuta S, "IL-25 causes apoptosis of IL-25Rexpressing breast cancer cells without toxicity to nonmalignant cells", Sci Transl Med, 3, pp.78~ (2011)
147. Ragonnaud E, "Tumor-derived thymic stromal lymphopoietin expands bone marrow b-cell precursors in circulation to support metastasis", Cancer Res, 79, pp.5826~5838 (2019)
148. Xie F, "Cervical carcinoma cells stimulate the angiogenesis through TSLP promoting growth and activation of vascular endothelial cells", Am J Reprod Immunol, 70, pp.69~79 (2013)
149. Xie F, "The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell", Cancer Lett, 364, pp.106~117 (2015)
150. Takahashi N, "Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T-cell lymphoma", Cancer Res, 76, pp.6241~6252 (2016)
151. De Monte L, "Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer", J Exp Med, 208, pp.469~478 (2011)
152. Demehri S, "Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis", J Clin Invest, 126, pp.1458~1470 (2016)
153. Yue W, "Thymic stromal lymphopoietin(TSLP)inhibits human colon tumor growth by promoting apoptosis of tumor cells", Oncotarget, 7, pp.16840~16854 (2016)
154. "A first-in-human, double blind, single dose study in healthy subjects and subjects with mild atopic asthma"[URL]
155. "A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 282 in healthy subjects and subjects with chronic rhinosinusitis with nasal polyps"[URL]
156. "A study to assess the efficacy and safety of MSTT1041A in participants with uncontrolled severe asthma"[URL]
157. "A study to assess the efficacy and safety of MSTT1041A in participants with moderate to severe atopic dermatitis"[URL]
158. "Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)"[URL]
159. "A study to evaluate the efficacy and safety of astegolimab in participants with chronic obstructive pulmonary disease"[URL]
160. "A study investigating the efficacy, safety, and PK profile of ANB020 administered to adult subjects with moderate-to-severe AD (ATLAS)"[URL]
161. "Proof of concept study to investigate ANB020 activity in adult patients with severe eosinophilic asthma"[URL]
162. "Etokimab in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP)"[URL]
163. "Placebo-controlled study to investigate ANB020 activity in adult patients with peanut allergy"[URL]
164. "A study to evaluate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Melrilimab (GSK3772847) in healthy participants"[URL]
165. "Efficacy and safety study of GSK3772847 in subjects with moderately severe asthma"[URL]
166. "Study of REGN3500 and dupilumab in patients with asthma"[URL]
167. "Study of safety, tolerability, and pharmacokinetics of multiple ascending doses of REGN3500 in adults with moderate asthma"[URL]
168. "Evaluation of SAR440340 and as combination therapy with dupilumab in moderate-to-severe asthma participants"[URL]
169. "Efficacy, safety, and pharmacokinetic profiles of REGN3500 administered to adult patients with moderate-to-severe atopic dermatitis"[URL]
170. "Efficacy and safety of REGN3500 monotherapy and combination of REGN3500 plus dupilumab in adult patients with moderate-to-severe atopic dermatitis"[URL]
171. "Proof-of-concept study to assess the efficacy, safety and tolerability of SAR440340 (Anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)"[URL]
172. "Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/Itepekimab in chronic obstructive pulmonary disease (COPD) (AERIFY-1)"[URL]
173. "Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/Itepekimab in chronic obstructive pulmonary disease (COPD) (AERIFY-2)"[URL]
174. "Safety and tolerability of MEDI3506 in healthy participants, in participants with COPD and healthy Japanese participants"[URL]
175. "Study to assess the efficacy and safety of MEDI3506 in adults with uncontrolled moderate-to-severe asthma (FRONTIER-3)"[URL]
176. "Efficacy and safety of MEDI3506 in adult subjects with atopic dermatitis"[URL]
177. "A phase II, randomized, double-blind, placebo-controlled study to assess MEDI3506 in participants with COPD and chronic bronchitis (FRONTIER-4)"[URL]
178. "A study to evaluate the pharmacokinetics of MEDI9929 (AMG 157) in adolescents with mild to moderate asthma"[URL]
179. "Study to evaluate the pharmacokinetics of tezepelumab in children with asthma (TRAILHEAD)"[URL]
180. "Double-blind, multiple dose study in subjects with mild atopic asthma"[URL]
181. "Safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis"[URL]
182. "Study to evaluate the efficacy and safety of MEDI9929 (AMG 157) in adult subjects with inadequately controlled, severe asthma"[URL]
183. "Effects of anti-TSLP in patients with asthma (UPSTREAM)"[URL]
184. "Study to evaluate tezepelumab on airway inflammation in adults with uncontrolled asthma (CASCADE)(CASCADE)"[URL]
185. "Phase 2a study to evaluate the efficacy and safety of MEDI9929 in adults with atopic dermatitis (ALLEVIAD)"[URL]
186. "Anti-TSLP (AMG 157) plus antigen-specific immunotherapy for induction of tolerance in individuals with cat allergy"[URL]
187. "Study to evaluate tezepelumab in adults with chronic spontaneous urticaria (INCEPTION)"[URL]
188. "Tezepelumab COPD exacerbation study (COURSE)"[URL]
189. "Study to evaluate tezepelumab in adults & adolescents with severe uncontrolled asthma (NAVIGATOR)"[URL]
190. "Study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma (SOURCE)"[URL]
191. "Long-term safety of tezepelumab in japanese subjects with inadequately controlled severe asthma (NOZOMI)"[URL]
192. "Extension study to evaluate the safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma (DESTINATION)"[URL]
193. "Study to evaluate tezepelumab in adults with severe uncontrolled asthma (DIRECTION)"[URL]
194. "Efficacy and safety of tezepelumab in participants with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT)"[URL]
195. "A bronchoprovocation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CSJ117 in adult subjects with mild atopic asthma"[URL]
196. "Study of efficacy and safety of CSJ117 in patients with severe uncontrolled asthma"[URL]
197. "Study of safety of CSJ117 in participants with moderate to severe uncontrolled asthma"[URL]
198. "Study of effect of CSJ117 on symptoms, pharmacodynamics and safety in patients with COPD"[URL]
199. Kelsen SG, "Astegolimab(anti-ST2)efficacy and safety in adults with severe asthma : a randomized clinical trial", J Allergy Clin Immunol, 148, pp.790~798 (2021)
200. Rabe KF, "Safety and efficacy of itepekimab in patients with moderate-to-severe COPD : a genetic association study and randomised, double-blind, phase 2a trial", Lancet Respir Med, 9, pp.1288~1298 (2021)
201. Emson C, "Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis : a post hoc analysis of the phase 2b PATHWAY study", J Asthma Allergy, 14, pp.91~99 (2021)
202. Menzies-Gow A, "Tezepelumab in adults and adolescents with severe, uncontrolled asthma", N Engl J Med, 384, pp.1800~1809 (2021)
203. Simpson EL, "Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis : a randomized phase 2a clinical trial", J Am Acad Dermatol, 80, pp.1013~1021 (2019)
204. Gauvreau G, "Late breaking abstract - efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients", Eur Respir J, 56, pp.3690~ (2020)

관련 논문AI추천